Clinical trials: Major Depressive Disorder, completed
Major Depressive Disorder
Prevalence of Major Depression Among Immigrants in Santiago, Chile
The general aim of this study is to explore the prevalence of major depressive disorder and the use of mental health services in the immigrant populations in the Metropolitan Region of Santiago, Chile. The hypotheses are: 1.
- Trial name
- STRING (NCT04114565)
- Where
- Chile
- Volunteers
- 1,092 people, healthy volunteers welcome
- Sponsor
- Pontificia Universidad Catolica de Chile
Major Depressive Disorder
A Study Comparing Duloxetine and Placebo in Assessing Energy and Vitality in Major Depressive Disorder (MDD) Patients
Study F1J-US-HMFS comprises two identical multicenter, 9-month, randomized, placebo-controlled, double-blind, trials (HMFSa and HMFSb).
- Trial name
- NCT00536471
- Testing
- Duloxetine hydrochloride
- Where
- 47 sites in United States, Puerto Rico
- Volunteers
- 776 people
- Sponsor
- Eli Lilly and Company
Treatment Resistant Depression
Low Field Magnetic Stimulation for Treatment Resistant Depression
This is a double-blind, randomized, sham-controlled phase II study of the effects of Low Field Magnetic Stimulation (LFMS) on brain circuitry of adults with treatment-resistant Major Depressive Disorder (MDD).
- Trial name
- NCT01944644
- Testing
- Active Low Field Magnetic Stimulation
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Weill Medical College of Cornell University
Major Depressive Disorder (MDD)
Light, Ion, and Fluoxetine Efficacy (LIFE) in Depression
This study will investigate the additional benefits of light and ion therapy as added treatments to an antidepressant (fluoxetine) in subjects with major depressive disorder (MDD), versus treatment with fluoxetine alone.
- Trial name
- NCT00958204
- Testing
- Light treatment, Negative ion therapy, Fluoxetine
- Where
- Canada
- Volunteers
- 134 people
- Sponsor
- University of British Columbia
Major Depressive Disorder
A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant Depression
The purpose of this study is to assess the efficacy of esketamine compared with placebo in improving symptoms of depression in patients with treatment resistant depression.
- Trial name
- NCT01640080
- Testing
- Esketamine
- Where
- 9 sites in Belgium, Germany and 1 more
- Volunteers
- 30 people
- Sponsor
- Janssen Research & Development, LLC
Major Depressive Disorder
Behavioral Activation for Major Depression With and Without Mindfulness
The objective of the study is to compare, in individuals who meet the diagnostic criteria for major depression, the effects of Behavioral Activation (BA) strictly behavioral with a BA protocol that includes mindfulness practices.
- Trial name
- NCT04768361
- Testing
- Behavioral Activation without Mindfulness, Behavioral Activation with Mindfulness
- Where
- Spain
- Volunteers
- 150 people
- Sponsor
- Hospital Miguel Servet
Depression
Pharmacogenetic Testing in an Outpatient Population of Patients With Depression
This is a randomized, control group design of pharmacogenetic implementation in a mental health population of subjects taking anti-depressants and/or anti-psychotics with a new or current primary or secondary diagnosis of Major…
- Trial name
- PGx-UPA (NCT02497027)
- Testing
- pharmacogenetic testing
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Avera McKennan Hospital & University Health Center
Major Depressive Disorder, Surgery
Intraoperative Ketamine Versus Saline in Depressed Patients Undergoing Anesthesia for Non-cardiac Surgery
This study evaluates whether ketamine, given as part of an anesthetic, improves depression symptoms in depressed patients undergoing non-cardiac surgery.
- Conditions
- Major Depressive Disorder, Surgery, Orthopedic Disorder
- Trial name
- NCT03861988
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Stanford University
Major Depression, Fibromyalgia
A Pilot Study of TMS Effects on Pain and Depression in Patients With Fibromyalgia
In this pilot study, the PI proposes to include 20 African American participants with Fibromyalgia to explore the effect of r TMS on pain and depressive symptoms.
- Trial name
- TMS (NCT00523302)
- Testing
- Active TMS
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Medical University of South Carolina
Major Depressive Disorder, Healthy Participants
A Study of the Neurobiology of Depression
Previous research studies have shown that depression is associated with changes in structure and activity in different parts of the brain and that antidepressant medication can affect brain activity in different parts of the…
- Trial name
- NCT01051466
- Testing
- Duloxetine
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Major Depressive Disorder
Fluoxetine vs. Brief Psychotherapy for Major Depression
In this study we compare two treatments for major depression - fluoxetine and brief psychodynamic psychotherapy. In addition to more traditional outcome measures, we also measure the densities of 5HT-1A and D-2 receptors before…
- Trial name
- NCT00714779
- Testing
- Fluoxetine, Short-term psychodynamic psychotherapy
- Volunteers
- 85 people
- Sponsor
- University of Turku
Depression, Dementia
RCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT)
The purpose of this study is to assess which antidepressants work the best in older adults who have treatment-resistant depression (TRD), and to test whether treatment-resistant late life depression is associated with declines in…
- Conditions
- Depression, Dementia, Mild Cognitive Impairment, Treatment Resistant Depression
- Trial name
- ONR (NCT05531591)
- Testing
- Aripiprazole Augmentation, Bupropion Augmentation, Switch to bupropion
- Where
- 4 sites in United States, Canada
- Volunteers
- 87 people
- Sponsor
- Centre for Addiction and Mental Health
Major Depressive Disorder
A Study of LY2216684 in Healthy Participants
This study will evaluate the pharmacodynamic and pharmacokinetic interaction of LY2216684 with alcohol in healthy participants. This study will run approximately for 34 days.
- Trial name
- NCT01380691
- Testing
- LY2216684, Alcoholic beverage
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Treatment Resistant Depression
Role Of Ketamine in Treatment-Resistant Major Depressive Disorder And Its Effect on Suicidality
In this study we will assess the effect of Ketamine infusion on depressive symptoms and in particular its effect on Suicidal behavior, ideation and thoughts in patients with treatment- resistant MDD.
- Trial name
- NCT04101474
- Testing
- Ketamine
- Where
- Egypt
- Volunteers
- 36 people
- Sponsor
- Assiut University
Post Traumatic Stress Disorder, Major Depressive Disorder
Accelerated TMS to a Novel Brain Target in MDD and PTSD
This is a Clinical Trial designed to evaluate novel transcranial magnetic stimulation (TMS) methods for treating depression/PTSD. TMS is an FDA-approved procedure for treatment-resistant depression.
- Trial name
- NCT03114891
- Testing
- Transcranial Magnetic Stimulation (TMS), Task, fMRI-guided TMS target
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Pennsylvania
Depression, Unipolar, Anxiety Disorder Social
Trans-diagnostic Group CBT vs. Standard Group CBT for Depression, Social Anxiety and Agoraphobia/Panic Disorder
Transdiagnostic Cognitive Behavior Therapy (CBT) delivered in the individual format, have been proven just as effective as traditional diagnosis specific CBT manuals.
- Conditions
- Depression, Unipolar, Anxiety Disorder Social, Panic Disorder
- Trial name
- TRACT-RCT (NCT02954731)
- Testing
- UP-CBT, Standard-CBT
- Where
- 4 sites in Denmark
- Volunteers
- 292 people
- Sponsor
- Psychiatric Research Unit, Region Zealand, Denmark
Major Depressive Disorder
Practicing Alternative Techniques to Heal From Depression: The PATH-D Study
This study is a randomized, controlled trial of Mindfulness-Based Cognitive Therapy (MBCT) versus Health-Enhancement Program (HEP) for patients with treatment-resistant major depressive disorder (MDD).
- Trial name
- PATH-D (NCT00871299)
- Testing
- Mindfulness Based Cognitive Therapy, Health Enhancement Program and medication management
- Where
- United States
- Volunteers
- 173 people
- Sponsor
- University of California, San Francisco
Major Depressive Disorder, Treatment Resistant
Nuedexta in Treatment-Resistant Major Depression
There is an urgent need, therefore, to identify well-tolerated, orally available compounds that target the NMDA receptor as a novel treatment approach for TRD.
- Trial name
- NCT01882829
- Testing
- dextromethorphan/quinidine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- James Murrough
Major Depressive Disorder
Study Evaluating DVS-233 SR in Elderly Outpatients With Major Depressive Disorder
To evaluate the overall safety and tolerability profile of two dose levels of DVS-233 SR during 6 months of open-label treatment in elderly outpatients with major depressive disorder.
- Trial name
- NCT00242229
- Testing
- DVS-233 SR
- Volunteers
- 52 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Psychotic Disorders
Treatment of MDEs During the Course of Psychotic Disorders With Duloxetine
We evaluate the efficacy and tolerability of duloxetine in the treatment of major depressive episodes during the course of psychotic disorders
- Trial name
- NCT00224302
- Testing
- Duloxetine
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Central Institute of Mental Health, Mannheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.